Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial

J. Harding, J. Cleary, G. Shapiro, I. Braña, V. Moreno, D. Quinn, M. Borad, S. Loi, I. Spanggaard, S. Stemmer, M. Dujka, R. Cutler, F. Xu, L. Eli, S. Macia, A. Lalani, R. Bryce, F. Meric Bernstam, D. Solit, D. HymanS. Piha-Paul

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)iv127
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Jul 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this